论文部分内容阅读
目的探讨西格列汀对T2DM小鼠的治疗作用及其机制。方法选取36只T2DM小鼠(8周龄),采用随机数字表法分为治疗(Treatment)组和对照(Control)组。Treatment组采用西格列汀灌胃治疗(80 mg/kg),Control组予等量蒸馏水灌胃,均为1次/d,连续给药5周,对比两组治疗前后血糖、FIns、Atg3、Atg12与Beclin1表达的变化情况。结果治疗后第3周、第5周Treatment组血糖低于Control组(P<0.05)。治疗5周后,Treatment组FIns、胰岛β细胞功能指数(HOMA-β)高于Control组(P<0.01),胰岛素抵抗指数(HOMA-IR)低于Control组(P<0.05)。Treatment组胰岛β细胞自噬相关因子Atg3、Atg12与Beclin1 mRNA相对表达值,以及Beclin1蛋白表达吸光度(OD)低于Control组(P<0.05)。结论西格列汀对T2DM小鼠有治疗作用,其作用机制可能与下调胰岛β细胞自噬相关因子Atg3、Atg12与Beclin1表达,以及改善胰岛β细胞功能有关。
Objective To investigate the therapeutic effect of sitagliptin on T2DM mice and its mechanism. Methods Thirty-six T2DM mice (8 weeks old) were selected and divided into treatment group and control group by random number table. In the treatment group, sitagliptin was administered intragastrically (80 mg / kg) and Control group was given the same amount of distilled water for 1 week / d for 5 weeks. The levels of blood glucose, FIns, Atg3, Atg12 and Beclin1 expression changes. Results The blood glucose in the treatment group was lower than that in the Control group (P <0.05) at the third week and the fifth week after treatment. After 5 weeks of treatment, FIns and β-cell function index (HOMA-β) in the treatment group were higher than those in the Control group (P <0.01), while the insulin resistance index (HOMA-IR) The expression of Atg3, Atg12 and Beclin1 mRNA in islet β-cell autophagy and the expression of Beclin1 protein in treatment group were lower than those in Control group (P <0.05). Conclusion Sitagliptin has a therapeutic effect on T2DM mice, and its mechanism may be related to the down-regulation of autophagy-related factors Atg3, Atg12 and Beclin1, and the improvement of pancreatic β-cell function.